ClinicalTrials.gov
ClinicalTrials.gov Menu

SPP100 Dose Finding Study in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00311012
Recruitment Status : Completed
First Posted : April 5, 2006
Last Update Posted : November 8, 2011
Sponsor:
Information provided by:
Novartis

Brief Summary:
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Aliskiren Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 445 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Dose-finding Study of SPP100 in Essential Hypertension
Study Start Date : August 2004
Actual Primary Completion Date : March 2005
Actual Study Completion Date : March 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Aliskiren




Primary Outcome Measures :
  1. Change from baseline in mean sitting diastolic blood pressure after 8 weeks

Secondary Outcome Measures :
  1. Change from baseline in mean sitting systolic blood pressure after 8 weeks
  2. Diastolic blood pressure less than 90 mmHg or 10 mmHg or greater change from baseline after 8 weeks
  3. Evaluate response to various doses by assessing the difference in mean sitting diastolic blood pressure after 8 weeks


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Mild to moderate essential hypertension
  2. Age: ≥20 years old and <80 years old (at time informed consent obtained)
  3. Sex: N/A
  4. Admission status: Outpatient

Exclusion Criteria:

  1. Pregnant women, lactating women, potentially pregnant women, or women who wish to become pregnant
  2. Patients having a mean sitting diastolic blood pressure of ≥110 mmHg and/or a mean sitting systolic blood pressure of ≥180 mmHg at either Visit 2 or 3
  3. Patients with secondary hypertension as a complication or patients suspected of having secondary hypertension(due to aortic coarctation, primary aldosteronism, coarctation of renal artery, renal hypertension
  4. Patients suspected of having malignant hypertension

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00311012


Locations
Japan
Novartis Pharmaceuticals
Tokyo, Japan
Sponsors and Collaborators
Novartis
Investigators
Principal Investigator: Novartis Pharmaceuticals, Japan Novartis Pharmaceuticals, Japan

ClinicalTrials.gov Identifier: NCT00311012     History of Changes
Other Study ID Numbers: CSPP100A1201
First Posted: April 5, 2006    Key Record Dates
Last Update Posted: November 8, 2011
Last Verified: June 2006

Keywords provided by Novartis:
Hypertension, Aliskiren

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases